Skip to content
The Kids Research Institute Australia logo
Donate

Search

A new phage discovery in the fight against Antimicrobial Resistance

Jack Canning, a PhD researcher in the Wal-yan Respiratory Centre’s Phage WA team, has made a significant finding in the search for alternative treatments to antimicrobial-resistant (AMR) bacteria.

Immune patterns linked to childhood asthma risk

New research digs deeper into how children's immune systems handle viral challenges

Unique twin study reveals clues to childhood allergies

A study published in Science Advances has revealed that while genetics play a significant role in shaping children's immune systems, environmental factors also influence key immune responses, offering opportunity for preventing allergic diseases.

Our team

Meet the team at Phage WA, who are working to tackle antimicrobial resistance (AMR) through phage therapy. 

Community Involvement

As part of our research development and planning we invite members of the community to work with us. Click here to find out how.

Contact Information

If you have any questions or would like more information about the Western Australian Epithelial Research Program (WAERP), please click here to access our contact details.

Conducting decolonizing research and practice with Australian First Nations to close the health gap

The purpose of this paper is to highlight a perspective for decolonizing research with Australian First Nations and provide a framework for successful and sustained knowledge translation by drawing on the recent work conducted by a research group, in five remote communities in North-Western Australia.

Current understanding of the neutrophil transcriptome in health and disease

Neutrophils are key cells of the innate immune system. It is now understood that this leukocyte population is diverse in both the basal composition and functional plasticity. Underlying this plasticity is a post-translational framework for rapidly achieving early activation states, but also a transcriptional capacity that is becoming increasingly recognized by immunologists.

Posaconazole-induced hypertension in children with cystic fibrosis

Posaconazole is a triazole antifungal with a broad spectrum of activity against moulds including Aspergillus spp. Emerging data suggest posaconazole may be effective in the treatment of allergic bronchopulmonary aspergillosis complicating cystic fibrosis.

Cystic fibrosis clinical isolates of aspergillus fumigatus induce similar muco-inflammatory responses in primary airway epithelial cells

Aspergillus is increasingly associated with lung inflammation and mucus plugging in early cystic fibrosis disease during which conidia burden is low and strains appear to be highly diverse. It is unknown whether clinical Aspergillus strains vary in their capacity to induce epithelial inflammation and mucus production.